Autoantibodies combined with systemic inflammation markers for predicting bone metastases in non-small cell lung cancer patients
-
By
-
Song Cheng
-
Dabin Chen
-
Rongrong Du
-
Chao Wang
-
Jiawen Xian
-
Liyuan Liu
-
Hong Wan
-
Ting Ye
-
May 26, 2026
-
Clinical Scorecard: Integrating Autoantibodies and Inflammatory Markers to Forecast Bone Metastasis Risk in Patients with Non-Small Cell Lung Cancer
At a Glance
| Category | Detail |
|---|
| Condition | Bone metastases in non-small cell lung cancer (NSCLC) |
| Key Mechanisms | Integration of autoantibodies and systemic inflammation markers |
| Target Population | Patients with non-small cell lung cancer |
| Care Setting | Oncology clinics and hospitals |
Key Highlights
- Nomogram developed to predict bone metastasis risk in NSCLC patients
- Incorporates seven key predictors including histology and autoantibodies
- Demonstrated good discriminatory ability with AUC of 0.921 in training cohort
Guideline-Based Recommendations
Diagnosis
- Utilize a nomogram model incorporating autoantibodies and inflammation markers for risk assessment
Management
Monitoring & Follow-up
- Regular assessment of autoantibody levels and inflammatory markers in NSCLC patients
Risks
- Bone metastases can lead to skeletal-related events
Patient & Prescribing Data
323 NSCLC patients treated at the Affiliated Hospital of Southwest Medical University
Incorporation of biomarkers may enhance treatment planning and monitoring
Clinical Best Practices
- Employ a comprehensive approach combining clinical, laboratory, and imaging data
- Utilize the nomogram for individualized risk prediction
Related Resources & Content
